# Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)

> **NCT00251576** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 4497 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** A-Phase: tirofiban; Z-Phase simvastatin
- **DRUG:** Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years
- **DRUG:** Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
- **DRUG:** Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours
- **DRUG:** Duration of Treatment: Z-Phase, 2 years.

## Key facts

- **NCT ID:** NCT00251576
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11-01
- **Primary completion:** 2004-03-23
- **Final completion:** 2004-03-23
- **Target enrollment:** 4497 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251576, "Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00251576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*